Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 1/2 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 33OTHER_GOV 3INDUSTRY 2UNKNOWN 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Thoracic 2

Conditions

Breast Neoplasms 55Carcinoma, Non-Small-Cell Lung 33Stomach Neoplasms 28Colorectal Neoplasms 26Small Cell Lung Carcinoma 19Lung Neoplasms 18Rectal Neoplasms 16Pancreatic Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Carcinoma, Hepatocellular 11Recurrence 10Leukemia, Myeloid, Acute 10Melanoma 9Esophageal Squamous Cell Carcinoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Head and Neck Neoplasms 7Hodgkin Disease 6Cholangiocarcinoma 6Adenocarcinoma of Lung 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Germ Cell and Embryonal 5

Interventions

Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Meningeal Carcinomatosis × Clear all
NCT05805631 2026-03-24

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Taipei Veterans General Hospital, Taiwan

Phase 2 Recruiting
23 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06971406 2025-05-14

FLAME-1

Henan Cancer Hospital

Phase 2 Not yet recruiting
100 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06441045 2024-06-04

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Fujian Cancer Hospital

Phase 2 Not yet recruiting
112 enrolled
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡